(NASDAQ: CRDF) Cardiff Oncology's forecast annual revenue growth rate of -32.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Cardiff Oncology's revenue in 2024 is $488,000.On average, 2 Wall Street analysts forecast CRDF's revenue for 2024 to be $21,668,427, with the lowest CRDF revenue forecast at $8,935,434, and the highest CRDF revenue forecast at $34,401,420. On average, 1 Wall Street analysts forecast CRDF's revenue for 2025 to be $8,935,434, with the lowest CRDF revenue forecast at $8,935,434, and the highest CRDF revenue forecast at $8,935,434.
In 2026, CRDF is forecast to generate $8,935,434 in revenue, with the lowest revenue forecast at $8,935,434 and the highest revenue forecast at $8,935,434.